Germany’s Boehringer Ingelheim and Cambridge, UK-based Autifony Therapeutics have announced a new collaboration focused on a novel therapeutic approach to a range of CNS disorders.
AstraZeneca and US biopharma Berg have entered a research pact to identify and evaluate novel targets and therapeutics to treat neurological disorders with the help of artificial intelligence. AZ also announced expanded approval in the US of breast cancer drug Faslodex.